Silence Therapeutics (SLN)
NASDAQ:SLN
Want to see SLN full AI Analyst Report?
SLN Stock Chart & Stats
$7.53
-$0.25(-3.72%)
At close: 4:00 PM EST
$7.53
-$0.25(-3.72%)
Day’s Range― - ―
52-Week Range$4.19 - $8.40
Previous CloseN/A
Volume50.54K
Average Volume (3M)101.05K
Market Cap
$283.41M
Enterprise Value$320.39M
Total Cash (Recent Filing)$70.08M
Total Debt (Recent Filing)$136.00K
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.32
Shares Outstanding47,234,610
10 Day Avg. Volume169,902
30 Day Avg. Volume101,050
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.61
Price to Sales (P/S)513.72
P/FCF Ratio-4.61
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue347.69
Enterprise Value/Gross Profit523.42
Enterprise Value/Ebitda-4.06
Forecast
1Y Price Target
$42.33Price Target Upside462.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$4.16M
Bulls Say, Bears Say
Bulls Say
Proprietary RNAi PlatformSilence’s owned delivery and chemistry platform (mRNAi GOLD) is a durable competitive asset: it underpins internal R&D and enables out-licensing and collaboration revenue streams. Platform ownership supports repeatable discovery, shortens new candidate development, and increases partner interest over multiple programs.
Low Financial LeverageMinimal debt gives the company long-term financial flexibility to fund clinical programs and weather biotech spend cycles without large fixed interest burdens. Low leverage reduces near-term default risk and preserves the ability to raise non-debt financing or execute opportunistic partnerships as trials progress.
Supportive Phase 1 Clinical Data (divesiran)Durable clinical proof-of-concept in PV materially improves the program’s commercial and partnering prospects: sustained effect, tolerability, and reduced procedure burden support less frequent dosing and a differentiated profile. These attributes strengthen long-term licensing, royalty, and eventual commercialization value if Phase 2 confirms results.
Bears Say
Sustained Negative Cash FlowPersistent negative operating and free cash flow means the company must repeatedly access external capital to fund R&D and trials. Over a multi-month horizon this creates dilution and execution risk, pressures partnership timelines, and constrains strategic optionality if capital markets tighten or milestone payments are delayed.
Large Operating And Net LossesDeep operating losses indicate the business is not self-funding and will continue consuming shareholder capital while advancing trials. Sustained negative profitability increases dependence on partners or financings, which can slow development or dilute existing holders and impacts ability to scale internal programs long-term.
Volatile, Minimal Revenue BaseHighly variable and currently minimal revenues mean operating spend is not covered by recurring cash inflows. This structural revenue volatility limits predictability for funding clinical programs and increases reliance on discrete collaboration milestones or equity raises to sustain development over the next several quarters.
Silence Therapeutics News
SLN FAQ
What was Silence Therapeutics’s price range in the past 12 months?
Silence Therapeutics lowest stock price was $4.19 and its highest was $8.40 in the past 12 months.
What is Silence Therapeutics’s market cap?
Silence Therapeutics’s market cap is $283.41M.
When is Silence Therapeutics’s upcoming earnings report date?
Silence Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 56 days.
How were Silence Therapeutics’s earnings last quarter?
Silence Therapeutics released its earnings results on May 07, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.129 by $0.019.
Is Silence Therapeutics overvalued?
According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued.
Does Silence Therapeutics pay dividends?
Silence Therapeutics does not currently pay dividends.
What is Silence Therapeutics’s EPS estimate?
Silence Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Silence Therapeutics have?
Silence Therapeutics has 47,234,610 shares outstanding.
What happened to Silence Therapeutics’s price movement after its last earnings report?
Silence Therapeutics reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.129. Following the earnings report the stock price went down -5.571%.
Which hedge fund is a major shareholder of Silence Therapeutics?
Currently, no hedge funds are holding shares in SLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Silence Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.33 (462.20% Upside)
$42.33 (462.20% Upside)
Hedge Fund Trend
Decreased
By 70.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-64.86%
12-Months-Change
Fundamentals
Return on Equity
-107.19%
Trailing 12-Months
Asset Growth
-37.87%
Trailing 12-Months
Company Description
Silence Therapeutics
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
SLN Stock 12 Month Forecast
Average Price Target
$42.33
▲(462.20% Upside)
Technical Analysis
Ownership Overview
22.15%
Insiders
0.10% Mutual Funds
32.00% Other Institutional Investors
45.19% Public Companies and
Individual Investors